NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback